This bill replaces current Section 174 with language that lets taxpayers deduct research and experimental expenditures as ordinary business expenses or, at their election, amortize them over a taxpayer‑selected period of not less than 60 months. It restores the pre‑Tax Cuts and Jobs Act treatment that had been largely removed beginning in taxable years after 2021, and adjusts related rules in sections 41 and 280C to align the R&D credit with the restored deduction.
For firms that engage in qualifying R&D the change improves near‑term cash flow and reduces book‑tax friction from forced capitalization. It also creates administrative and transition tasks for the IRS, corporate tax teams, and any taxpayer that earlier began capitalizing R&D under the post‑2017 rules — because the amendments are effective for taxable years beginning after December 31, 2021, and interact with existing R&D credit mechanics and controlled‑group rules.
At a Glance
What It Does
The bill rewrites Internal Revenue Code Section 174 to let taxpayers immediately deduct qualifying research and experimental expenditures paid or incurred in a taxable year, or elect to treat such amounts as deferred expenses amortizable over at least 60 months. It preserves exclusions (land, exploration) and keeps reasonableness limits.
Who It Affects
R&D‑intensive companies (manufacturing, biotech, pharma, software), startups and smaller firms sensitive to cash flow, corporate tax and accounting teams, tax advisers, and the IRS. Multinational enterprises with foreign R&D are specifically affected because they previously faced longer amortization periods for offshore expenditures.
Why It Matters
Reinstating immediate expensing materially alters after‑tax project economics and investment timing for R&D; it also reintroduces a substantial revenue and policy trade‑off between incentivizing innovation and preserving the tax base, while creating a short run compliance burden as taxpayers and IRS reconcile prior capitalization elections and credit interactions.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill replaces Section 174 with statutory text that restores the long‑standing ability to treat research and experimental (R&E) expenditures as deductible business expenses. Under the new language a taxpayer may elect to treat qualifying R&E costs paid or incurred in a taxable year as current deductions; alternatively, at the taxpayer’s election (made on or before the return filing deadline), such costs may be treated as deferred and amortized ratably over a taxpayer‑selected period of not less than 60 months, beginning in the month the taxpayer first realizes benefits from the expenditures.
The statute preserves the old exclusions for land and exploration and retains a ‘‘reasonable amount’’ limitation.
Mechanically, the bill allows a taxpayer to adopt the expensing method for the first taxable year in which qualifying expenditures are paid or incurred without the Secretary’s consent; changes after that generally require IRS approval. The amortization election must be made no later than the time prescribed for filing the return for the taxable year (including extensions), and once a method (and amortization period) is adopted it governs that year and subsequent years unless changed with IRS approval.
These procedural rules echo prior practice but will require firms that previously capitalized R&D for 2022+ to revisit method elections and, where relevant, file amended returns or seek guidance.The legislation also makes conforming edits to the R&D tax credit rules. It replaces prior cross‑references in section 41 and substantially revises section 280C(c) to address how deductions interact with the credit: generally, taxpayers cannot deduct the portion of qualified research expenses equal to the credit, but the bill preserves an election that yields a reduced credit (calculated net of corporate tax) if a taxpayer prefers to retain full deductions — that election is made on the return and is irrevocable.
The bill applies these changes to taxable years beginning after December 31, 2021, which means the statutory change is effectively retroactive to the first year taxpayers were required to capitalize R&D under the post‑TCJA rules.
The Five Things You Need to Know
The bill restores the pre‑TCJA option to deduct research and experimental expenditures as current business expenses rather than forcing capitalization.
If a taxpayer does not deduct, the law permits an amortization election with a minimum amortization period of 60 months, starting when the taxpayer first realizes benefits from the expenditures.
A taxpayer may adopt the expensing method for the first taxable year with qualifying expenditures without IRS consent; any later change generally requires approval.
Section 280C(c) is rewritten: taxpayers generally lose the deduction for the portion of research expenses equal to the R&D credit, but may elect an irrevocable reduced credit (net of tax) instead.
The amendments apply to taxable years beginning after December 31, 2021, so they reach tax years that were previously subject to mandatory capitalization under the post‑2017 rules.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the statute the American Innovation and R&D Competitiveness Act of 2025. Practically, this is the bill’s label; it has no substantive effect on tax treatment but signals the legislative intent to prioritize competitiveness in R&D tax policy.
Allow current deduction; rules for adopting methods
Rewrites subsection (a) to permit taxpayers to treat qualifying research or experimental expenditures ‘‘as expenses which are not chargeable to capital account’’ and deduct them in the year paid or incurred. It also sets out method‑adoption mechanics: a taxpayer may adopt that method for the first taxable year with such expenditures without IRS consent; later elections or changes generally require Secretary approval. That administrative language matters because it limits when taxpayers must seek IRS permission and defines the default rule for subsequent taxable years.
Amortization election and timing
Creates a separate amortization path: at the taxpayer’s election (made by the return filing deadline per Treasury regulations), qualifying expenditures not deducted may be treated as deferred expenses and amortized ratably over a taxpayer‑selected period of not less than 60 months. The amortization must begin with the month the taxpayer first realizes benefits. The provision reiterates that once a method/period is chosen it governs subsequent taxable years unless changed with IRS approval; it also clarifies that the election cannot apply to expenditures incurred before the year of election.
Exclusions and reasonableness; clerical fix
Reaffirms that Section 174 does not cover expenditures for acquisition or improvement of land, property subject to depreciation or depletion, or exploration for minerals (including oil and gas). It retains a ‘‘reasonable amount’’ requirement for eligible research expenditures. The bill also updates the part VI table of sections to reflect the rewritten Section 174 — a bookkeeping step that ensures cross‑references in the Code point to the new text.
Aligns the R&D credit and deduction rules
Alters Section 41(d)(1)(A) cross‑reference language and replaces Section 280C(c) with text that modifies the interaction between the R&D credit and deductions. The new 280C(c) prevents a deduction for that portion of qualified research expenses equal to the credit, and it preserves a taxpayer election for a reduced credit computed net of tax (with strict timing and irrevocability requirements). The provision also confirms that controlled‑group rules for the credit continue to apply.
Effective date
Makes the amendments effective for taxable years beginning after December 31, 2021. That backward‑reaching effective date brings the change into the period when taxpayers were required to capitalize R&D under current law, raising transition issues for returns already filed and for taxpayers that began amortizing R&D costs.
This bill is one of many.
Codify tracks hundreds of bills on Finance across all five countries.
Explore Finance in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- R&D‑intensive corporations (biotech, pharmaceutical, software, advanced manufacturing): they regain immediate deductibility that improves near‑term cash flow and reduces the after‑tax cost of undertaking research projects.
- Startups and early‑stage companies with heavy R&D spend: because many lack current taxable income, the ability to expense R&D reduces initial tax accounting frictions and simplifies funding models tied to tax attributes.
- Multinational firms with foreign R&D operations: these firms benefit particularly where post‑TCJA law required longer amortization periods for foreign expenditures; restoring deduction or shorter amortization narrows the prior disadvantage for offshore R&D.
Who Bears the Cost
- U.S. Treasury (federal revenues): immediate expensing reduces near‑term corporate taxable income and therefore expected receipts compared with mandatory capitalization/amortization rules.
- Internal Revenue Service and tax administrators: they must implement transition guidance, process possible amended returns, and resolve methodology questions (e.g., when benefits are ‘‘first realized’’), adding administrative burden.
- Corporate tax and accounting teams and external advisers: firms that began capitalizing or amortizing R&D under the prior regime must revisit elections, possibly amend tax returns, and reconcile book‑tax differences — a compliance cost and planning exercise.
Key Issues
The Core Tension
The central dilemma is straightforward: immediate expensing improves firms’ cash flow and incentives to invest in R&D, but it reduces near‑term tax revenue and complicates administration and transition for taxpayers who already capitalized research costs; the statute chooses to prioritize competitiveness and cash flow while shifting the burden of resolving implementation complexity to Treasury, taxpayers, and the courts.
The bill resolves one policy problem — easing tax treatment for R&D — while creating several implementation questions that will matter in practice. First, the retroactive effective date to taxable years beginning after December 31, 2021 means many taxpayers and the IRS must confront returns filed under the capitalization regime.
The statute does not supply explicit transition mechanics for amended returns, carryforwards, or basis adjustments beyond referencing section 1016 for capital account treatment; Treasury guidance will be necessary to settle how prior amortization schedules, cumulative deductions, and basis adjustments unwind or convert without producing double‑counting or undercounting of deductions.
Second, the interplay with section 280C’s rewritten language generates choice architecture that matters: a taxpayer can either forgo a deduction equal to the credit or make an irrevocable election for a reduced credit computed net of tax. That calculation ties the credit value to the corporate tax rate and can produce materially different outcomes depending on the taxpayer’s marginal rate, timing of deductions, and whether the taxpayer is profitable.
Finally, operational definitions — especially ‘‘first realizes benefits’’ to trigger amortization start, the scope of ‘‘reasonable’’ amounts, and how controlled‑group rules allocate elections — are under‑specified. Those gaps create planning opportunities, but they also risk inconsistency across IRS rulings and litigated outcomes if Treasury does not issue clear regulations and transitional rules.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.